Despite the guideline-recommended use of both SGLT2i and GLP-1RA therapy, there is a paucity of real-world evidence on the long-term effects of combining SGLT2is with newer generation GLP-1RAs (including once-weekly GLP-1RAs, once-daily oral semaglutide, and dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] agonists) on metabolic outcomes and other cardiorenal outcomes [22]
Available at: 99 KaryekarC.DonovanM.AllenE.FlemingD.RavichandranS.ChenR
Patients taking compounded GLP-1s (with same active ingredients as Mounjaro and Zepound) were found to lose on average 22.5% of their body weight in comparison to 15% of those on semaglutide (Ozempic, Wegovy)
Despite not being a primary aim of the study, by collecting participant characteristics we saw clinically significant improvements in physical health (weight and HbA1c), of similar magnitude to that seen in trials of GLP-1 receptor agonists in obesity [35] and T2D and overweight [36, 37]
Ingredients: L-Carnitine L-Tartrate, vegetable capsule (HPMC), anti-caking agents (Magnesium Sterate INS470(iii)
The simulation made one point very clear: every consumer behaves differently, and one-size-fits-all guidance will not work
